Page 117 - அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021

Share this article Share this article SAN DIEGO, March 10, 2021 /PRNewswire/ Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company s synthetic lethal PRMT5 inhibitor during a late-breaking minisymposium at the American Association for Cancer Research (AACR) Virtual Annual Meeting taking place April 10-15, 2021. At Mirati, we are applying leading-edge drug discovery strategies, such as synthetic lethality, to translate this exciting research approach into meaningful, targeted therapeutic options for patients with cancer, said James Christensen, Ph.D., executive vice president and chief scientific officer, Mirati Therapeutics, Inc. We look forward to presenting early preclinical data at AACR from our internally-discovered, potentially first-in-class, synthetic lethal PRMT5 inhibitor, as an example of how Mirati is progressing the science of novel targets.

United statesMatthew marxPriyanka shahJames christensenTemre johnsonExchange commissionAmerican association for cancer researchMirati therapeutics incMirati therapeuticsAmerican associationCancer researchVirtual annual meetingBreaking minisymposiumஒன்றுபட்டது மாநிலங்களில்மேத்யூ மார்க்ஸ்பிரியாங்க ஷா

Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy

Share this article HOLON, Israel, March 9, 2021 /PRNewswire/ Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a review article titled Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis reviewing the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy. The peer-reviewed article, published in Cancer Discovery, a journal of the American Association for Cancer Research, was co-authored by Drew Pardoll, M.D., Ph.D., Professor of Oncology, Johns Hopkins University and Chairman of Compugen s Scientific Advisory Board. Article highlights include: Detailed overview of the DNAM-1 axis including axis checkpoint molecules: DNAM-1, TIGIT, PVRIG and CD96, along with their ligands PVR and PVRL2

United statesTel avivElana holzmanJosephine belluardoBob yedidJohns hopkins universityLifesci advisorsCompugen ltdCorporate communications compugen ltdExchange commissionAmerican association for cancer researchLifesci communicationsSecurities exchangeTel aviv stock exchangeCheckpoint receptorsCancer discovery

Study finds increased risk of death among breast cancer patients who drink sugar-sweetened soda

E-Mail IMAGE: Study first author Nadia Koyratty is an epidemiology PhD candidate in the University at Buffalo School of Public Health and Health Professions. view more Credit: University at Buffalo BUFFALO, N.Y. New research from the University at Buffalo suggests that breast cancer patients who drink sugar-sweetened beverages regularly are at increased risk for death from any cause and breast cancer in particular. Compared to women who never or rarely drank non-diet soda, those who reported drinking non-diet soda five times or more per week had a 62% higher likelihood of dying from any causes, and were 85% more likely to die from breast cancer specifically. The findings were published online ahead of print March 2 in

United statesNew yorkJol freudenheimMaurizio trevisanDavid hillSusan mccannAmy millenNadia koyrattyNevin universityRoswell park comprehensive cancer centerNational cancer instituteUb school of public healthEnvironmental healthHealth professionsArmy medical researchAmerican association for cancer research

Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy

Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesTel avivElana holzmanJosephine belluardoBob yedidJohns hopkins universityLifesci advisorsCompugen ltdCorporate communications compugen ltdExchange commissionAmerican association for cancer researchLifesci communicationsSecurities exchangeTel aviv stock exchangeCheckpoint receptorsCancer discovery

Study reveals association between walking pace and risk of death among cancer survivors

Study reveals association between walking pace and risk of death among cancer survivors
aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.

United statesElizabetha salernoNational cancer instituteNational institutes of healthUniversity of north carolinaWashington university school of medicineAmerican association of retired personsWashington universityAmerican association for cancer researchGeorge washington universityHealth studyWashington university schoolNational institutesNorth carolinaCancer epidemiologyAmerican association